COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

RESIST-2: 2nd-line ART for HIV-2 Infection (RESIST-2)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03394196
Recruitment Status : Active, not recruiting
First Posted : January 9, 2018
Last Update Posted : January 22, 2020
Clinique des Maladies Infectieuses, CHNU de Fann, Dakar, Senegal
Centre de Sante de Ziguinchor, Casamance, Senegal
Janssen Pharmaceutica
Merck Sharp & Dohme Corp.
National Institute of Allergy and Infectious Diseases (NIAID)
Information provided by (Responsible Party):
Geoffrey S. Gottlieb, University of Washington

No Study Results Posted on for this Study
Recruitment Status : Active, not recruiting
Estimated Primary Completion Date : May 31, 2020
Estimated Study Completion Date : July 2022